US EditionHow OMass Therapeutics Is Tackling Congenital Adrenal Hyperplasia, A Rare Genetic Disorder - Data Intelligence
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
How OMass Therapeutics Is Tackling Congenital Adrenal Hyperplasia, A Rare Genetic Disorder - Data Intelligence
Ros Deegan is an industry leader and the CEO of OMass Therapeutics, an Oxford-based biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. OMass’s MC2 program targeting Congenital Adrenal Hyperplasia, or CAH, is set to enter the clinic this year and in our interview today she walks me through how the company is preparing for their trials, how their approach …
How OMass Therapeutics is tackling congenital adrenal hyperplasia, a rare genetic disorder - Beyond Biotech - the podcast from Labiotech
Ros Deegan is an industry leader and the CEO of OMass Therapeutics, an Oxford-based biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. OMass’s MC2 program targeting Congenital Adrenal Hyperplasia, or ...
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
